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Abstract 
Inspired by microvesicle-mediated intercellular communication, we propose a hybrid vector 
for magnetic drug delivery. It consists of macrophage-derived microvesicles engineered to 
enclose different therapeutic agents together with iron oxide nanoparticles. Here, we 
investigated in vitro how magnetic nanoparticles may influence the vector effectiveness in 
terms of drug uptake and targeting. Human macrophages were loaded with iron oxide 
nanoparticles and different therapeutic agents: doxorubicin, tissue-plasminogen activator (t-
PA), disulfonated tetraphenylchlorin (TPCS2a) and 5,10,15,20-tetra(m-
hydroxyphenyl)chlorin (mTHPC). The hybrid cell microvesicles were magnetically 
responsive, readily manipulated by magnetic forces and MRI-detectable. Using 
photosensitizer-loaded vesicles, we showed that the uptake of microvesicles by cancer cells 
could be kinetically modulated and spatially controlled under magnetic field and that cancer 
cell death was enhanced by the magnetic targeting.  
Keywords: cell microvesicles, drug targeting, magnetic nanoparticles, magnetic 
manipulation, magnetofection. 
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Introduction  
One of the main issues to improve therapeutic outcome in cancer therapy as well as in the 
treatment of other diseases consists in limiting off-target toxicity while providing high local 
drug concentrations at the site of interest. Active approaches rely on drug delivery systems 
that enable to recognize the target and/or to induce delivery or retention at the target by 
stimuli. 
1, 2
 Regarding the former, specific ligands may be attached to the drug delivery 
surface in order to specifically bind moieties that are overexpressed or mostly present on the 
target. 
3, 4
 Concerning the latter, targeting may be based on the presence of specific enzymes 
or pH changes at the target site or externally-triggered by light, ultrasound or magnetic field 
stimuli. 
5, 6
 
High magnetic susceptibility of the iron oxide core enables non-invasive manipulation of 
magnetic drug delivery systems by the application of a magnetic field gradient. Localized 
magnetically-assisted capture of magnetic drug carriers at the site of interest, termed 
“magnetic targeting”, has been investigated in vitro, 7 in preclinical 8-11 and in clinical 
settings.  
12, 13
 While the concept of magnetic drug targeting has been proposed more than 30 
years ago,  
14
 the efficacy of magnetic drug targeting has been essentially investigated for 
synthetic drug delivery systems. 
15-17
 Little attention has been focused on designing biogenic 
drug delivery systems enabling magnetic targeting of drugs, and more particularly applicable 
to hydrophilic, hydrophobic, amphoteric drugs as well as drugs with high molecular weight.  
Inspired by microvesicle-mediated intercellular communication, 
18
 we have recently proposed 
a naturally-derived drug delivery system. It consists of microvesicles shed by cells that are 
engineered to enclose exogenous cargoes. 
19, 20
 Microvesicles are originated by direct budding 
from the cell plasma membrane. Microvesicle release may be either constitutive or 
consequent to cell stimulation by physical or chemical stress. 
21
 Shed microvesicles bring 
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along membrane components and cytoplasmic contents from parent cells. Cell microvesicles 
are recognized as important effectors in the intercellular exchange of biological signals 
between not only neighboring cells but also cells at remarkable distance. 
21
 This takes place 
since cell microvesicles widely circulate in the vasculature. The estimated microvesicle 
concentration in the peripheral blood of healthy individuals is 5–50 µg/ml. The majority of 
these microvesicles are originated from blood cells, mainly platelets. The second larger 
population of circulating microvesicles is derived from mononuclear phagocyte cell lineage. 
22
 Therefore, it would be reasonable to choose such cell lineage for the design of a biogenic 
drug delivery system. Additionally, macrophages are capable of efficiently internalizing a 
wide range of materials, which is an important asset for loading the exogenous 
drug/nanoparticle cargo before the release of such materials in the shed cell microvesicles. 
Thereby, macrophage-derived microvesicles may represent a unique promise in converting an 
autologous intrinsically biocompatible sub-cellular entity into a drug delivery system able to 
carry both nanoparticles and drugs. In this regard, it would be of interest to demonstrate that 
cell microvesicles may be loaded with different drug molecules while simultaneously 
enclosing nanoparticles that enable spatially-controlled drug delivery. While the 
encapsulation of different drug molecules would represent a proof of versatility, the 
demonstration of their targeting potential would enable the drug to be concentrated at the site 
of interest avoiding off-target effects and reducing toxicity. 
Hence, the aim of this study was to co-encapsulate drugs and magnetic nanoparticles in cell-
derived microvesicles and investigate how the magnetic particles may influence the 
performance of cell-derived hybrid microvesicles as drug delivery systems. At first, we 
investigated if microvesicle drug loading could be extended to different drug molecules 
irrespective to their molecular weight, hydrophobic, hydrophilic and amphiphilic character. 
Next, we showed how iron oxide nanoparticles enclosed in hybrid microvesicles could enable 
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spatio-temporal microvesicle magnetic manipulation. We then focused on the photosensitizer-
loaded microvesicles to evidence the magnetic control of both cellular uptake and cell death. 
In this regard, magnetic targeting of microvesicles was analyzed at the macroscopic scale by 
MRI, at the cellular scale by confocal microscopy and at the subcellular level by electron 
microscopy.  
Methods 
Loading THP-1 macrophages with magnetic nanoparticles and drugs 
In this study, we aimed to investigate if microvesicles secreted by macrophages could be 
loaded with several types of drugs. Drugs with different physico-chemical properties were 
chosen: doxorubicin, tissue-plasminogen activator (t-PA), disulfonated tetraphenylchlorin 
(TPCS2a) and 5,10,15,20-tetra(m-hydroxyphenyl)chlorin (mTHPC) (Table 1). Doxorubicin is 
an amphoteric drug (protonable amino group and deprotonable phenolic group) 
23
 considered 
to be a molecule of intermediate solubility (log P = 0.71). 
24
 This antitumor drug has been 
widely used in clinics for the treatment of a broad spectrum of cancers, although 
cardiomyopathy is a major adverse side effect. 
25
 t-PA is a hydrophilic macromolecule of 527 
amino acids presenting a molecular weight of 68 kDa. 
26
 It is a thrombolytic agent used for 
the treatment of acute ischemic stroke, whose main adverse effect is hemorrhage. 
27
 TPCS2a 
was selected as an amphiphilic molecule. 
28
 It is a negatively charged photosensitizer drug 
with endosomal localization within cells that is investigated for photochemical internalization 
(PCI). 
29
 mTHPC is a reduced porphyrin that has been investigated as a photosensitizer drug 
for two decades until being considered nowadays an established cancer drug on the market. It 
is a neutral hydrophobic molecule, as such it can cross the plasma membrane and then 
redistribute among the membranes of organelles in the cytoplasm. 
30, 31
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The magnetic iron oxide nanoparticles (Fe2O3) were produced by alkaline co-precipitation of 
FeCl2 and FeCl3 salts, according to Massart’ procedure.
32
 Their molarity was measured by 
atomic emission spectroscopy.  
THP-1 cells, previously treated with phorbol 12-myristate 13-acetate (PMA) (Supplementary 
Figure 1), were incubated with drugs and nanoparticles (5 mM iron in serum-free RPMI 
medium supplemented with 5 mM sodium citrate) either simultaneously (2-hour co-
incubation of drug and nanoparticles at 37°C) or sequentially (2-hour incubation with drug 
followed by 2-hour incubation with nanoparticles) in order to verify if the presence of 
nanoparticle could change the amount of uptaken drug. Incubation was followed by 2 
washings in serum-free RPMI medium and an overnight chase in order to allow nanoparticle 
internalization by cells. In brief, incubation step was conducted in serum-free medium, while 
the chase step was carried out in the presence of serum. This was followed by serum-free 
incubation step to trigger vesicle release, as further disclosed in the next sub-section. Drug 
concentration was 0.5 -10 µM for mTHPC (Frontier Scientific) and TPCS2a (PCI Biotech), 
10µM for doxorubicin (Sigma) or 0.05µM for t-PA-FITC (Abcam).  
Microvesicle release by precursor cells, purification and characterization 
In order to stimulate microvesicle release, THP1-macrophages were cultured in serum-free 
medium for 2 days. Serum depletion induces cell stress and the subsequent release of cell 
microvesicles. 
33
  Microvesicle purification from the conditioned starvation medium was 
performed by magnetic sorting by means of a magnet which creates a magnetic field of B = 
650 mT, and a magnetic field gradient gradB = 55 T m
–1
 in the volume of the syringe 
(Supplementary methods). 
19
 Magnetic sorting was performed after a previous centrifugation 
step for eliminating apoptotic bodies and dead cells (1125 g for 10 min). Microvesicles were 
characterized in terms of size, polydispersity index, zeta potential, drug internalization and 
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magnetic targeting potential at a microscopic and macroscopic level by 
micromagnetophoresis and MRI, respectively (Supplementary methods). 
For micromagnetophoresis, microvesicles were inserted in a glass slide/coverslip chamber 
featuring an integrated nickel microrod. When the microrod was magnetized by a permanent 
magnet, the local magnetic field generated at its extremity attracted magnetic objects toward 
the micromagnet, covering the tip (Supplementary methods). 
Microvesicle uptake  
Cancer cells were incubated with mTHPC magnetic microvesicles (0.5 µM mTHPC) for 30 
minutes, 2 hours or overnight at 37°C. Alternatively, in some experiments, cancer cells 
incubation with microvesicles was performed at 4°C during 30 minutes. Confocal 
experiments of microvesicle uptake were carried by using PKH-label on microvesicle 
membrane. In addition to that, lysosomes of recipient cancer cells were stained with 
Lysotracker.  Further method details are provided in the supporting material. 
Microvesicle uptake and induced cell death under a magnetic field gradient 
The spatial modulation of drug uptake by magnetic targeting was analysed for SKOV-3, TC1 
and PC3 cells. Cancer cells were seeded in culture dishes presenting a diameter of 35 mm. 
Dish surface was virtually divided in three equal parts (further details are provided in the 
supporting material) and a magnet was placed at one of the edges. A magnetic field strength 
of 150 mT was employed (rectangular magnet). Following PBS washing, the cells were 
incubated with 1 mL of magnetic mTHPC microvesicles or mTHPC in solution at 0.5 µM for 
2 hours in the dark at 37°C in a humidified 5% CO2 atmosphere, with the magnet in position.  
After PBS washing, and magnet removal, culture dishes were incubated overnight with 
complete medium and then were analysed by confocal microscopy. Alternatively, the three 
surface parts were scraped individually and the collected cells of each fraction (the one near 
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the magnet, the central fraction and the one far from the magnet) were separately lysed using 
triton X-100 at 0.3% final concentration. Drug concentration in each fraction was determined 
by fluorescence spectroscopy, as mTHPC is a fluorescent molecule. 
Experiments on microvesicle-induced cell death under a magnetic field gradient were 
performed in the same conditions of uptake experiments and then cells underwent or not a 
laser exposure step using a 650-nm diode laser at a light fluence of 10J (100 mW/cm² for 100 
s). Cell death was evaluated by propidium iodide assay and MTT test. Further method details 
are provided in the supporting material. 
Results  
Loading of macrophages with both drugs and magnetic nanoparticles   
We first investigated the initial uptake of drugs by macrophages after simultaneous or 
sequential incubation with iron oxide nanoparticles by confocal microscopy (Supplementary 
Figure 2). Doxorubicin, TPCS2a, and mTHPC uptake was observed by direct drug 
fluorescence emission. For t-PA, uptake was evaluated via the fluorescence emission of its 
FITC-conjugated molecule. Iron oxide nanoparticle co-incubation did not influence the uptake 
of doxorubicin nor t-PA. As expected, doxorubicin displayed a nuclear localization which is 
in agreement with its action of interfering with DNA replication via DNA intercalation. t-PA 
localized into the cytoplasm, as already observed for astrocytes. 
34
 
Interestingly, the uptake of TPCS2a and mTHPC was quantitatively enhanced by co-
incubation with nanoparticles (Supplementary Figure 3). Supplementary Figure 4 
demonstrates the simultaneous internalization of photosensitizer drugs and nanoparticles. 
Magnetic nanoparticles were identified into endosomes/lysosomes which magnetically 
aligned one another in presence of a magnetic field. Red fluorescence from TPCS2a was 
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observed in endosomes/lysosomes colocalizing with nanoparticles or widespread in cytoplasm 
due to mTHPC (Supplementary Figure 4). 
Production of cell-shed microvesicles loaded with the drugs and the magnetic nanoparticles 
Once macrophages were loaded with both iron oxide nanoparticles and drugs, cells were 
cultured for 2 days in serum-free medium in order to trigger microvesicles release. The 
microvesicle production method used herein was based on cell stress induced by serum 
deprivation. 
35
 Such pro-apoptotic stimulus elicits phosphatidylserine translocation to the 
outer membrane leaflet. Microvesicles have intermediate size (200 nm - 1 µm) between 
exosomes and apoptotic bodies and result from remodeling of cell membrane and formation 
of outward protrusions. 
36-39
  Serum deprivation allows triggering microvesicle shedding 
without any chemical or biomolecule. Therefore, no further processing is required to 
eliminate the vesiculation trigger agent.  A centrifugation step was carried out in order to set 
aside the subpopulation of apoptotic bodies from microvesicle one. As a last step, cell-shed 
microvesicles were magnetically sorted overnight in order to select iron oxide loaded 
microvesicles. 
Microvesicle characterization 
Microvesicles presented an average hydrodynamic size of 673 ± 168 nm (Supplementary 
Figure 5), which is in keeping with characteristic microvesicle size range from 200 nm to 
1000 µm.
39
 A polydispersity index of 0.3 was obtained, which is also in agreement with 
natural broad size distribution of microvesicles. A zeta potential of -30 mV was observed, 
indicating a negatively charged surface.  
To demonstrate the loading of drug and nanoparticles in microvesicles, a magnetophoresis 
technique was used to record microvesicle trajectories in the presence of a magnetic field 
gradient created by a micromagnet (Figure 1a). All obtained microvesicles, irrespective to the 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
10 
 
drug, successfully accumulated at the micromagnet tip (Figure 1b). Micromagnetophoresis 
set-up was also carried out under fluorescence microscopy. Images showed that the attracted 
microvesicles emitted the characteristic fluorescence of the drug to which precursor 
macrophages were incubated, indicating that the drug was encapsulated in microvesicles. The 
fact that microvesicles emitted drug fluorescence while presenting magnetic attraction 
confirmed that they were loaded with both iron oxide nanoparticles and the drug. Such 
observations also demonstrate the magnetic targeting potential of the produced vectors. 
Fluorescence emission peaks characteristic of each drug could also be detected in the lysate of 
purified microvesicles as observed in Supplementary Figure 6. 
The magnetic targeting potential of drug-loaded magnetic microvesicles was also studied at 
the macroscopic level by MRI. Agarose solutions containing microvesicles were allowed to 
gel at 4°C either in the absence or in the presence of a magnet (Supplementary Figure 7) 
before MRI scanning. Agarose phantoms without magnet presented well-dispersed signal 
voids distributed uniformly throughout the sample corresponding to susceptibility artefacts 
created by the iron-oxide-loaded vesicles. In comparison, when gelled in the presence of the 
magnet, the agarose phantom displayed a hyposignal zone close to the magnet, which 
demonstrates magnetic attraction of the microvesicles.   
In order to gain further insight into the effect of a magnetic field in the kinetics and spatially-
controlled drug uptake and therapeutic effect, mTHPC-loaded magnetic vesicles were then 
chosen for the next experiments.  
Internalization of microvesicles by cells 
Microvesicle uptake experiments were performed with SKOV-3 human ovarian cancer cells 
and PC3 human prostate cancer cells. In order to visualize microvesicle internalization, 
microvesicle membrane was stained with a PKH membrane dye. It consists of a lipophilic 
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molecule with long aliphatic tails presenting high affinity for membranes. Staining takes place 
by partitioning of the lipophilic dye into lipid regions of cell or vesicle membranes. 
Endocytosis of microvesicles was first confirmed by colocalization of PKH-staining with 
magnetically-responsive endosomes which were able to align in the direction of a magnetic 
field (Supplementary Figure 8).  Additional uptake experiments, in which the lysosomes of 
recipient cells were labelled with Lysotracker, were performed. As presented in Figure 2 and 
Supplementary Figure 9, until 2 hours of incubation, green fluorescence from microvesicle 
membrane did not colocalize with lysosomes. This may be attributed to the delay 
microvesicles require reaching lysosomal compartments. Colocalization was partially 
evidenced after overnight incubation. In fact, green spots were observed in the same plane of 
lysosomes but they did not completely overlay. This may potentially result from a concurrent 
mechanism for entering the cell. Experiments of microvesicle internalization by cells were 
also carried out at 4°C (Supplementary Figure 10) and showed that the temperature restraint 
of the endocytosis pathway did not prevent microvesicles to be uptaken by cells. Indeed, it has 
been reported in the literature that exosomes circumvent endocytotic pathway via a direct 
fusion with cell membrane. 
40
 The same may potentially apply to microvesicles. 
A magnetic field gradient accelerates the transfer of the drug loaded microvesicles into 
cancer cells  
Microvesicles were incubated with SKOV-3 cells in the presence of a magnet generating a 
magnetic field gradient which was constant along the cell culture surface while varying 
perpendicularly, as indicated in Figure 3a. mTHPC uptake kinetics mediated by free drug in 
solution and by mTHPC magnetic microvesicles in the presence or not of a magnetic field 
were quantified by means of a calibration curve (Supplementary Figure 11).  At 30 minutes, 
the free drug in solution promoted higher drug uptake than the microvesicles. This is likely 
due to the fast transfer of free drugs compared to the transfer of drugs protected by 
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microvesicle membrane. A such time-delayed uptake compared to the free drug in solution, 
has already been reported for other vectors either of synthetic or of natural origin 
41, 42
. 
However, when incubated with drug-loaded microvesicles, an almost 2-fold enhancement (P 
<0.02) in drug uptake could be observed at the earliest time point in the presence of the 
magnet. After 2 hours, drug uptake increased up to 0.8 fmol/cell irrespective to the condition, 
which remained nearly the same for the following times (6h and 18h) (Figure 3b).  
Magnetic targeting of microvesicles to cancer cells  
Spatial targeting of microvesicles was next assessed on SKOV-3 cells incubated with PKH67-
stained microvesicles in the presence of a magnet generating a magnetic field gradient along 
the culture surface (Figure 4a). Confocal microscopy imaging revealed that fluorescence 
emission from PKH67-stained microvesicle membrane as well as from mTHPC drug cargo 
was very low in the region distal to the magnet. In contrast, the closer from the magnet, the 
higher the fluorescence emission from both microvesicle membrane and drug cargo (Figure 
4b). Consistently, quantitative analysis from fluorescence spectroscopy of SKOV-3 cell lysate 
revealed a 20-fold higher drug concentration in the magnet region compared to the spatially 
opposite area (Figure 4c). Due to their magnetic cargo, microvesicles experienced an 
increased magnetic force with decreasing distance from the permanent magnet. As a result, 
microvesicles were attracted to the close proximity of the magnet, thus modulating their 
interactions with SKOV-3 cells. Similar results were obtained with murine cervical cancer 
TC-1 cells (Supplementary Figure 12) and human prostate cancer PC3 cells (Supplementary 
Figure 13).  
The magnetic cell targeting was also evaluated at the subcellular scale by TEM analysis of 
cancer cells after incubation with microvesicles in the presence of a magnetic field gradient. 
TEM micrographs revealed abundant electron-dense endosomes in the cytoplasm of cells at 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
13 
 
the magnet region, indicating an important uptake of iron oxide nanoparticles. Alternatively, 
only few electron-dense endosomes could be visualized in cells located in the region distal to 
the magnet (Figure 4d).  
Taken together, these results highlight the remarkable effect of magnetic targeting in the 
spatial modulation of drug uptake in vitro. 
Magnetically-modulated therapeutic effect   
We then investigated if the targeting effect could induce a magnetically controlled cell death. 
After cancer cells were incubated with magnetic mTHPC microvesicles in the presence of the 
magnet, the entire plate was irradiated at 650 nm at a light fluence of 10 J (100 mW/cm
2
) 
during 100 s in order to activate the photosensitizer. Cell death was analyzed by confocal 
microscopy using propidium iodide staining (Figure 5a). Propidium iodide staining increased 
as the distance from the magnet decreased, revealing enhanced necrosis induction in the 
magnet region. Conversely, cells incubated to magnetic drug-free microvesicles were negative 
to propidium iodide staining in the magnet region after laser exposure. The same applies to 
non-irradiated SKOV-3 cells at the magnet, intermediate and distal regions when incubated 
with magnetic mTHPC microvesicles (Supplementary Figure 14). Data from MTT test 
(Figure 5b) was quite in agreement with propidium iodide assay. Metabolic activity was 
drastically reduced when cancer cells incubated with magnetic mTHPC microvesicles in the 
magnet region were exposed to laser while comparing to negative control. Such effect was 
observed in a lesser extent at the intermediate zone and no statistically significant difference 
was observed for the laser exposed distal region condition, the laser exposed magnetic 
(mTHPC-free) microvesicle condition at the magnet region or laser exposed magnet region 
condition when compared to negative control.   
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As it can be observed, the obtained data demonstrated that cells in the magnet region exposed 
to laser after incubation with drug-free microvesicles presented no impact in cell viability and 
metabolic activity. This indicates that the magnetic microvesicle itself induced no detrimental 
effect. Additionally, magnetic field alone had no effect on cell viability. The obtained 
therapeutic effect for the condition of magnetic mTHPC microvesicles exposed to laser in the 
magnet region results from the magnetically induced accumulation of the vesicles in the 
magnet region which enhanced local drug concentration and cytotoxicity when laser exposure 
was applied. No significant difference was found in cell metabolic activity after cell 
incubation with magnetic mTHPC microvesicles without laser exposure compared to control 
(P = 0.1154), as it can be observed in Supplementary Figure 15.  
 
Discussion 
In this study, we investigated cell microvesicles as biogenic vectors for magnetically targeting 
drugs of different molecular weight and hydrophilic/hydrophobic characters. Some authors 
have already succeeded in loading purified exosomes with a siRNA or anti-inflammatory 
drugs. 
43-46
 For siRNA, loading was achieved by the transient disruption of exosome 
membrane via electroporation. 
43
 The anti-inflammatory drug curcumin was loaded into 
exosomes by a different method. Due to the drug hydrophobicity, curcumin loading could be 
performed via hydrophobic interactions with exosomes membrane. 
44
  Herein, we tested a 
different approach as the loading step was not applied directly to purified vesicles. Instead, we 
proposed a top-down approach in which the parent cell was loaded with both drug and 
magnetic nanoparticles in order to act as a fabrication unit to produce microvesicles laden 
with the dual cargo. The obtained results show that nanoparticles internalization in 
macrophages can be effective together with any of the drug tested, and that both mTHPC and 
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TPCS2a molecules take advantage of nanoparticle uptake in order to further penetrate the cell, 
which can be beneficial for a more effective drug load into the final delivery system.  
The co-encapsulation of different drugs with magnetic nanoparticles within microvesicles 
opens interesting perspectives. On one side, TPCS2a-loaded magnetic microvesicles would 
represent a smart biogenic drug vector potentially enabling both magnetic targeting and light-
induced drug release. On the other side, microvesicles loaded with doxorubicin or t-PA would 
be of interest for drug targeting to improve treatment efficacy while limiting the important 
side effects of these drugs. 
The proof of magnetic targeting potential of microvesicles loaded with the tested drugs was 
provided by a micromagnetophoresis experiment demonstrating the attraction of the different 
microvesicles toward a micromagnet. Besides, magnetic nanoparticles within microvesicles 
could promote temporal controlled uptake of microvesicles. Magnetic field promoted faster 
drug uptake kinetics. These kinetic results indicate that a magnetic field influenced the 
kinetics of microvesicle uptake but did not increase the absolute amount of uptaken drug.  The 
obtained results are consistent with investigations on the mechanisms of magnetofection, 
which consists in enhancing gene delivery by magnetic force. It has been reported that 
magnetic force does not induce increased endosomal uptake when the superparamagnetic 
gene vectors are accumulated on the cellular surface. The efficiency of magnetofection was 
assigned to the accelerated sedimentation of the magnetic gene vector complexes. 
47
 Indeed, 
magnetofection was found to lower the required dose of vectors and to reduce incubation 
time, which might be important for in vivo application where the time of contact with the 
target cell is usually short. 
47, 48
  
Besides influencing the drug uptake kinetics, the magnetic field also induced an important 
spatial modulation of uptake. Indeed, magnetic targeting effect was demonstrated at the 
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macroscopic scale by MRI, at the cellular level by confocal microscopy and at the subcellular 
scale by TEM. Indeed, magnetic targeting has already been confirmed in the literature in the 
macroscopic scale by MRI or at the cellular level. 
16, 49, 50
 However, to our knowledge, it is the 
first time that magnetic targeting proof is simultaneously provided at this three scale levels. 
Additionally, magnetic targeting was attested by investigating the spatial distribution of the 
components of microvesicles: membrane, drug cargo and iron oxide nanoparticles. Magnetic 
targeting effect was demonstrated via anisotropic drug uptake as well as anisotropic cell 
death. Results obtained from the spatial modulation of mTHPC uptake by magnetically 
guided drug targeting suggest that the magnetic cargo from the hybrid microvesicles may 
enhance selective drug accumulation at target site potentially implying lower therapeutic 
doses and reduced side effects. 
In brief, we reported herein an approach to engineer microvesicles to enclose an exogenous 
therapeutic cargo by using parental cells loaded with magnetic nanoparticles and drugs 
presenting different physicochemical properties. Such bio-mimetic platform enabled drug 
delivery in spatio-temporal controlled manner by means of magnetic actuation, enhancing 
cancer cell death by magnetic targeting. Our strategy may be considered a “one for all” 
approach as the platform is suitable for loading different sets of drugs. Our procedure is also 
versatile as microvesicles could be virtually produced from a broad array of cell types. Such 
vectors could be therefore provided with specific endogenous targeting properties, inherited 
from precursor cells. Considering a product development perspective, such versatility is quite 
important. Additionally, microvesicles could be produced in bioreactors for scaling-up.  
Regarding a clinical standpoint, immune tolerance could be achieved in the case of vesicles 
obtained from autologous patient cells. Nevertheless, all these points have yet to be 
thoroughly assessed in order to foresee a clinical translation. Current and future progress in 
deciphering the mechanisms of microvesicle interplay with the organism may raise exciting 
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new opportunities for converting cell-released vesicles into a new generation of intrinsically 
biocompatible drug carriers translatable to clinic. 
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Figure/Table legends 
 
Table 1: Physico-chemical properties and clinical use 
24, 26-28, 33, 34
 of the investigated drugs. 
 
Figure 1: (a) Micromagnetophoresis set-up featuring a glass slide/coverslip chamber to which 
a 50 µm diameter nickel microrod was integrated. Magnetization of the nickel microrod is 
provided by a rectangular magnet positioned perpendicular to the micromagnet. (b) 
Micromagnetophoresis experiment of microvesicles obtained from THP-1 macrophages 
incubated 2h with 5 mM iron oxide nanoparticles and 5 µM mTHPC (first line), 5 µM 
TPCS2a (second line), 0.05 µM t-PA-FITC (third line) or 10 µM doxorubicin (fourth line) – 
bright field on the left and fluorescence images on the right.  
Figure 2: Confocal microscopy of SKOV-3 cells labelled with a lysosomal marker 
(Lysotracker in blue color) incubated with microvesicles previously stained with a membrane 
dye (PKH in green color) as a function of the time. Fluorescence emission from PKH-labelled 
vesicle membrane (first column), Lysotracker (second column), and a merge (third column) 
are presented. 
Figure 3: (a) Representation of microvesicle-mediated uptake of mTHPC under a magnetic 
field. (b) mTHPC uptake as a function of the time for SKOV-3 cells incubated with mTHPC 
in solution or mTHPC magnetic microvesicles in the presence or not of a magnetic field (n≥3; 
* indicates P < 0.05 and NS means not statistically significant).  
Figure 4: (a) Representation of microvesicle-mediated uptake of mTHPC under a magnetic 
field gradient. (b) Confocal microscopy of SKOV-3 cells after incubation with mTHPC 
magnetic microvesicles (0.5 µM drug load) in the presence of a magnetic field gradient for 
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2h: green fluorescence from microvesicle membrane (first column), red fluorescence from 
mTHPC (second column), blue fluorescence from Dapi-stained nuclei (third column), and 
merge (fourth column). (c) Quantification of the intracellular mTHPC load by fluorescence 
spectroscopy as a function of the distance from the magnet (n=3). (d) Transmission electron 
microscopy of PC3 cells incubated with microvesicles in the presence of a magnetic field 
gradient for 2h. Cells presented abundant electron-dense endosomes in the magnet region 
(upper line) while they were scarcely observed for cells located in the region distal to the 
magnet (bottom line). Insets represent higher magnification views. 
Figure 5: (a) Confocal microscopy of SKOV-3 cells after incubation with magnetic mTHPC 
microvesicles in the presence of a magnetic field gradient and laser exposure at 650 nm at a 
fluence of 10 J (100 mW/cm²) for 100 s: first, second and third lines. Cells incubated with 
magnetic (drug-free) microvesicles in the presence of a magnetic field gradient and exposed 
to laser are shown in the fourth row. Cells not incubated with microvesicles but in the magnet 
region and exposed to laser are presented in the fifth row, while cells solely exposed to laser 
are displayed in last row. Bright field images (first column) as well as fluorescence emission 
from mTHPC (second column), propidium iodide (third column), and a merge (forth column) 
are presented. (b) Metabolic activity obtained by MTT test for the same conditions described 
right above (*** indicates P < 0.0001; ** indicates P < 0.01 and NS means not statistically 
significant for n≥3). 
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Table 1 
 m-THPC TPCS2a t-PA Doxorubicin 
MW (Da) 681 777 68,000 544 
Chemical 
character 
Hydrophobic Amphiphilic Hydrophilic Intermediate 
solubility 
Clinical 
use 
Photosensitizer 
anticancer drug 
 
Photochemical 
internalization agent 
under clinical trial 
Thrombolytic 
drug 
Anticancer drug 
(DNA intercalating) 
Abbreviations: m-THPC: m-tetra hydroxyphenyl chlorin; TPCS2a: disulfonated 
tetraphenylchlorin; t-PA: tissue plasminogen activator. 
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Graphical abstract text 
 
Cell-derived microvesicles were engineered to enclose drugs and co-encapsulate magnetic 
nanoparticles. The uptake of microvesicles by cancer cells could be kinetically modulated and 
spatially controlled under magnetic field.   
